PDI204

Phase 1Small molecule

UUniversity of Melbourne

PDI204 is one of 27 small molecule programs targeting COVID-19. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Phase 1

Active, not recruiting

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Stivarga

Bayer

Preclinical

1 2

Aimovig

Amgen

Preclinical

1 3

Aldactone

Pfizer

Preclinical

1 4

Nexavar

Bayer

Preclinical

1 5

Calciferol

Activella

Tricor

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Benadryl

PParkedale

Preclinical

1 10

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-191 trial

A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19

Active, not recruiting·UUniversity of Melbourne·Phase 1·NCT06965751·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PDI204. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PDI204 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PDI204. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Melbourne company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Melbourne

PDI204

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-191 trial

References

Drug Info

Quick Facts

Related News